THYROIDIAN DYSFUNCTIONS AT THE PATIENTSWITH CHRONIC ACTIVE HEPATITIS WITH HVB AND HVC PREVIOUSLY AND AFTER THE TREATMENT WITH PEG INTERFERON α 2A 180 μg
Abstract:
The fundamental idea and the objective of this observational study were the optimisation of the
treatment with Peginterferon α 2A administrated weekly to the patients with chronic active hepatitis with
hepatitic virus B and C and the co-existance of thyroid dysfunctions. During the interval 1st of January 2005 -
1 January 2010 we followed 2 lotes of patients: 115 patients with chronic hepatitis with HVC, in treatment
with Peginterferon α2A in a dose of 180 μg / week associated with Ribavirină in a daily dose, correlated with
the weight, respectively 125 patients with chronic hepatitis with HVB in treatment with Peginterferon α2A in a
dose of 180 μg / week, with the aim of establishing the frecquency of apparition of the thyroid dysfunction in
the context of the specific treatment.Concomitantly, it has been pursued the establishing of age correlations,
the sex correlations, the degree of activity of the disease,the possible moment of the infestation and the
apparition of the clinical and paraclinical thyroid modifications.
full text article in English (.EN) |